At Tuesday's annual meeting, Valeant's turnaround promises didn't turn to ashes in its hands. Why? Maybe because it has a laundry list of assets to sell for cash. Or maybe because big investors kept mum.
Valeant says it’s going to make good on its promise to discount the sky-high prices on its heart drugs Nitropress and Isuprel--but only after the NYT pointed out that those discounts were, so far, missing in action.